Nestlé announced on Tuesday that it had acquired a package of rights to Vowst, a drug derived from fecal microbiota, from Seres Therapeutics.

In a press release, its clinical nutrition subsidiary Nestlé Health Science justifies its decision by the success of these capsules since their launch in the United States last year.

The Swiss group - which has been responsible for marketing the capsules on the US market since their launch in June 2023 - will now have full control over both development and manufacturing.

Produced from human stool, Vowst is an orally-administered treatment that has been approved by the FDA to prevent the recurrence of clostridium difficile (C. difficile) infections.

Copyright (c) 2024 All rights reserved.